Clinical trial
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With…
NCT00241020 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00241020 |
|---|---|
| Title | Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma |
| Official title | Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Advanced Hepatocellular Carcinoma |
| Intervention type | Drug |
| Interventions | Octreotide |
| Enrollment | 270 |
| Start date | Jun 1, 2002 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Oct 18, 2005 |
| Last update posted | Apr 12, 2016 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: